Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Corsair Gaming Inc (CRSR) Price & Performance

AbCellera Biologics IncTrade
Corsair Gaming IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Corsair Gaming Inc — how do they compare? AbCellera Biologics Inc trades at $10.3 (market cap $2.99B), while Corsair Gaming Inc trades at $12.82 (market cap $1.39B). The key difference: AbCellera Biologics Inc is far larger — about 2.2× Corsair Gaming Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Corsair Gaming Inc nearer its low. Which is the better fit depends on your goals.

ABCLCRSR
Market Cap
$2.99B$1.39B
Sector
HealthTechnology
52-Week High
$9.76$14.35
52-Week Low
$2.78$4.58
Enterprise Value
$2.58B$1.38B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.

The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.

Corsair Gaming Inc

Corsair Gaming (CRSR) trades at $12.92, down 5.76% in the last session, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates and raising full-year guidance, while recent acquisitions like Trak Racer and AI product launches aim to drive growth. However, the stock faces valuation concerns with a high P/E ratio of 41.39 and inconsistent profitability, as net income turned positive only in 2026 after previous losses.

The outlook is mixed: improved cash flow and strategic expansions support upside potential, but high valuation and competitive pressures pose risks. Analyst consensus is cautious with a $12.40 price target below the current price, suggesting limited near-term gains despite recent operational improvements.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Corsair Gaming Inc

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment

Read more on CRSR